Pre-Test Advancing the Management of NSCLC: A Focus on Emerging Therapies Pre-Test Which of the following statements regarding tumor treating fields (TTFields) is TRUE? They deliver electric currents through transducer arrays surgically implanted inside the tumor They deliver high intensity, intermediate frequency, fixed electric currents to tumor cells They disrupt cellular senescence, leading to cell cycle arrest and apoptosis They use alternating electric fields which interfere with dividing cells and tumor growth Unsure In the pivotal phase 3 LUNAR trial, TTFields in combination with which of the following met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in OS over standard therapies alone in patients with stage 4 NSCLC following progression while on or after treatment with platinum-based chemotherapy? Atezolizumab and bevacizumab Gemcitabine or nab-paclitaxel ICI or docetaxel Weekly paclitaxel Unsure Which of the following dermatologic adverse events occurred most frequently in the EF-15 pilot study of TTFields therapy with pemetrexed in NSCLC and usually improved with topical steroid treatment? Epidermolysis bullosa Hidradenitis suppurativa Rash/Dermatitis Vitiligo Unsure How often do you consider the use of newer/emerging treatment approaches for the management of NSCLC? Always Often Sometimes Rarely Never
